DYSIS achieves Clinical and Cost Benefits

DYSIS Medical Ltd

(DYSIS or the Company)

DYSIS Cervical Cancer Screening Tool Achieves
Clinical and Cost Benefits to Patients

Study commissioned by NIHR HTA programme on behalf of NICE highlights sensitivity and benefits of DYSIS over conventional methods

Edinburgh – 28 March 2012 – DYSIS Medical Ltd, the medical devices company in female health, today announced that its cervical cancer screening colposcopy technology has been assessed under an independent review for clinical and cost effectiveness and achieved outstanding results.

DYSIS colposcopy uses spectral imaging to help clinicians highlight any areas of concern by mapping out the condition of a woman’s cervix.  In clinical trials, it has been shown to significantly boost sensitivity in detecting cervical cancer in its earliest stages.  Armed with this additional information, clinicians are able to take immediate steps to treat patients and prevent disease progression.

The assessment looked at the clinical and cost effectiveness of a variety of different products to improve the capability of cervical screening. It was commissioned by the NIHR HTA programme on behalf of the National Institute for Health and Clinical Excellence (NICE).

To read the report, please visit: https://www.nice.org.uk/guidance/dg32

The report found that DYSIS colposcopy had higher sensitivity than conventional colposcopy.  The results of the economic analysis suggested that DYSIS colposcopy was less costly and more effective than colposcopy alone and that these results were robust to the numerous sensitivity analyses that were undertaken.

Cervical cancer is the second most common cancer in women and accounts for more than one in ten (9%) of diagnosed female cancers.  The World Health Organization estimates that there are over 500,000 new cases each year resulting in 250,000 deaths. In the developed world, where screening programmes are used, some 30 million women will receive an abnormal smear test result and be called for a colposcopy examination.  If caught and treated at an early stage, there is a high degree of treatment success.

The introduction of cervical cancer screening in women over 25 has helped to reduce the incidence of the disease – about 4.4 million women are screened in the UK each year – even so, approximately, 900 women in England a year die of the disease and the cost to the healthcare services, including the NHS runs into multimillions.

As a result of these findings, if the DYSIS product was adopted more widely in the UK, the Company believes many more women could be identified and treated for the disease earlier using much less expensive and traumatic interventions.

Alastair Atkinson, DYSIS Medical CEO commented on the report, “The DYSIS product is already used in hospitals throughout Europe and we’ve had a highly positive reception to initial sales in the US following our FDA clearance to market. The DYSIS product is already having a major impact on women’s health in other countries and we hope to do the same in the UK.”

For more information, please contact:

DYSIS Medical LtdTel: +44 (0)1506 592159

Alastair Atkinson, CEO

College Hill (PR for DYSIS Medical)Tel: +44 (0)20 7457 2020

Melanie Toyne Sewell / Gemma Howe

Email: dysis@collegehill.com

 Notes to Editors

 DYSIS Medical Ltd

DYSIS Medical Ltd has its global headquarters in Edinburgh. The company is committed to saving lives through the early detection and diagnosis of disease using biophotonic innovations. It aims to be the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications. For more information, please visit: www.dysismedical.com

The DYSIS cervical cancer screening product employs advanced photonics and computer assistance to quantify and map the aceto-whitening process – providing clinicians with reliable information to assist in the identification of pre-cancerous lesions. The product is sold in Europe and the US.